BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Sep. 28, 2004
View Archived Issues
New peptide sulfonamides and their use as integrin receptor modulators
Read More
New antitumor agents and their use in ALL therapy
Read More
Novel glucagon antagonists covered by Merck patent
Read More
Phamacopeia scientists claim new IL-8 receptor modulators
Read More
Novartis presents new cathepsin S inhibitors with utility in neuropathic pain
Read More
Daiichi scientists prepare and test new factor Xa inhibitors
Read More
New antibacterial agent isolated from Fundibacter sp. by Japanese researchers
Read More
Merck KGaA grants vilazodone rights to Genaissance
Read More
European approval for Angiox for use in PCI
Read More
New perspectives in the use of sumatriptan to treat migraine
Read More
RGH-896 demonstrates in vivo analgesia
Read More
Lower infection rate found in some volunteers after receiving bivalent HIV vaccines
Read More
Patient recruitment starts in a phase I clinical trial with DAC:GRF
Read More
IND submission to begin clinical testing of Tarvacin
Read More
Clinical trials confirm the efficacy of ropinirole in PD and RLS
Read More
Advisory Committee recommends approval of Menactra
Read More
Long-term clinical evaluation of three treatments for early PD
Read More
Pivotal study begins for FavId for follicular B-cell NHL
Read More
NF-kappaB Decoy set to enter phase I/II trial in 2005
Read More
Canadian sites approved to join pivotal Veronate study
Read More
Promising early results for escitalopram in treatment of kleptomania
Read More
RegeneRx files to begin phase II study of TB4 for chronic pressure ulcers
Read More
Enrollment completed in phase III study of Canvaxin
Read More
Sopherion licenses North American rights to Myocet
Read More
Paladin Labs realigns product pipeline
Read More
Alimta approved in Europe for malignant pleural mesothelioma and NSCLC
Read More
Enrollment under way in Modrenal prostate cancer study
Read More
Sertraline demonstrates potential in treating bulimia
Read More
DNA vaccine for anthrax effective in rabbit model
Read More